edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Medigene is a publicly listed, Germany-based, immuno-oncology platform company focused on the development of T cell receptor (TCR)-guided therapies with the aim of effectively eliminating cancer.
Medigene hosted an R&D event on its 3S (specific, sensitive and safe) T cell receptors (TCRs), designed for precision immunotherapies. Management highlighted the versatility of these TCRs across TCR-engineered T cell (TCR-T) therapies, TCR-guided T cell engager (TCR-TCE) therapies and TCR-natural killer cell (TCR-NK) therapies. Dr David Zhen outlined the MDG1015 lead program, showcasing its novel approach to treating solid tumours. The webinar also highlighted Medigene’s end-to-end platform, which combines multiple modular technologies for developing diverse TCR-guided therapies.
Get access to the very latest content matched to your personal investment style.